Financière de Tubize SA Shares float
What is the Shares float of Financière de Tubize SA?
The Shares float of Financière de Tubize SA is 19.180M 43.12%
What is the definition of Shares float?
Shares float is the portion of shares of a corporation that are in the hands of public investors as opposed to locked-in stock.
= annual shares outstanding - closely held shares
Shares float represents the portion of shares of a corporation that are in the hands of public investors as opposed to locked-in stock held by promoters, company officers, controlling-interest investors, or government. This number is sometimes seen as a better way of calculating market capitalization because it provides a more accurate reflection of what public investors consider the company to be worth. In this context, the float may refer to all the shares outstanding that can be publicly traded
The float is calculated by subtracting the locked-in shares from outstanding shares. Stocks with smaller floats tend to be more volatile than those with larger floats. In general, the large holdings of founding shareholders, corporate cross-holdings, and government holdings in partially privatized companies are excluded when calculating the size of a public float.
Shares float of companies in the Health Care sector on EURONEXT compared to Financière de Tubize SA
What does Financière de Tubize SA do?
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
Companies with shares float similar to Financière de Tubize SA
- Cogeco Communications has Shares float of 19.147M 61.46%
- Celebrity Fashions has Shares float of 19.151M 40.09%
- Polaris Infrastructure has Shares float of 19.161M 98.63%
- Jackson Acquisition has Shares float of 19.170M 86.16%
- IOL Chemicals and Pharmaceuticals has Shares float of 19.176M 32.67%
- Atacama Copper has Shares float of 19.177M 55.79%
- Financière de Tubize SA has Shares float of 19.180M 43.12%
- Rice Acquisition has Shares float of 19.194M 80.89%
- Volt has Shares float of 19.195M 69.88%
- New Providence Acquisition has Shares float of 19.208M
- CRISIL has Shares float of 19.209M 26.49%
- Select Interior Concepts has Shares float of 19.209M 75.22%
- Bonheur ASA has Shares float of 19.218M 45.18%